ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2025

Oct 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2025-10-06

Reporting Person: Rizvi Syed Ali-aamir (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-06	Common Stock	A	283018	—	Acquired	283018	Direct
2025-10-06	Common Stock	A	62893	—	Acquired	345911	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-06	Stock Option (right to buy)	$3.18	A	383854	Acquired	2035-10-06	Common Stock (383854)	Direct

Footnotes

F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

F2: Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries.

F3: Represents non-qualified stock options ("NQSOs") that convert to common stock on a one-for-one basis. One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.